Autopsy report · NCT00545298

Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers

“Strategic direction of the sponsor changed”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 1 month before it stopped.
• 4 participants enrolled.
• Results were posted on the registry 4 years after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Nitric BioTherapeutics, Inc

Sponsor type

Industry

Conditions

Venous Ulcers

Interventions

Nitric Oxide - same dose 6 wks; Nitric Oxide modified treatment

Participants

4

Sites

1

Countries

United States

Trials that died the same way

• Effects of Dietary Supplements on Nail and Hair Health
  “Strategic change by sponsor” (91% match in meaning)
• Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
  “sponsor strategy change” (90% match in meaning)
• POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)
  “Change in Sponsor strategy” (89% match in meaning)
• Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19
  “Sponsor's strategic decision” (88% match in meaning)
• Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness
  “Strategic decision of Sponsor” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.